Beckman Coulter Launches 2012 Discovery in Motion Tour
Beckman Coulter Life Sciences (Brea, California) recently launched its nationwide Discovery in Motion tour, a mobile exhibit equipped with state-of-the-art laboratory instrumentation that will travel coast-to-coast throughout the continental United States, with a few stops scheduled in Canada.
Beckman Coulter Life Sciences (Brea, California) recently launched its nationwide Discovery in Motion tour, a mobile exhibit equipped with state-of-the-art laboratory instrumentation that will travel coast-to-coast throughout the continental United States, with a few stops scheduled in Canada. The tour started in San Diego, offering application demonstrations performed by a team of scientific experts.
“We are extremely excited with the launch of the Discovery in Motion tour,” Scott Atkin, president of Beckman Coulter, said. “This mobile laboratory allows us to reach our customers in ways we never could before. By delivering live, up close demonstrations of our products, we are able to provide researchers with a richer experience.”
The tour is designed for laboratory directors, principal investigators, laboratory technicians, staff scientists, and anyone involved in life sciences, chemistry, and materials research. Each stop will provide visitors with a variety of activities. Researchers can experience a personalized demonstration, meet colleagues, and receive information to stay up-to-date on the latest science and technology available from Beckman Coulter. Capillary electrophoresis, centrifugation, liquid handling, particle characterization, and flow cytometry products will be on display for the initial leg of the tour, and products will be added as new technologies become available.
For more information and a list of tour dates, visit www.lifesciencediscoverytour.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
